934461-40-2
Chemical Structure
POT-4
Synonym(s): AL-78898A
- CAS No.: 934461-40-2
- Formula:C72H102N22O18S2
- Molecular Weight:1627.85
InChIKey: VNWKTOKETHGBQD-UHFFFAOYSA-N
SMILES: C(C=1C=2C(N(C)C1)=CC=CC2)[C@H]3C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=4C=5C(NC4)=CC=CC5)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC6=CN=CN6)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(N[C@@H]([C@@H](C)O)C(N)=O)=O)CSSC[C@H](NC([C@H]([C@H](CC)C)NC(C)=O)=O)C(=O)N[C@@H](C(C)C)C(=O)N3
Biological Activity: POT-4 (AL-78898A), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 can be used for age-related macular degeneration research[1][2]
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
POT-4 | 98.88% | POT-4 (AL-78898A), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 can be used for age-related macular degeneration research | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.82
HY-P1717AMY-101 -
Similarity Score 0.80
HY-P1036Compstatin -
Similarity Score 0.75
HY-P11905FcIII peptide -
Similarity Score 0.69
HY-P3171Acetyl-(Cys4,D-Phe7,Cys10)-a-MSH (4-13) -
Similarity Score 0.67
HY-P1216HS014 -
Similarity Score 0.67
HY-P1215HS024 -
Similarity Score 0.67
HY-P4764LY2112688 -
Similarity Score 0.66
![Ac-c[Cys-Glu-His-d-Phe-Arg-Trp-d-Cys]-Pro-Pro-Lys-Asp-NH2 Chemical Structure](//file.medchemexpress.com/product_pic/hy-p4665.gif)
HY-P4665Ac-c[Cys-Glu-His-d-Phe-Arg-Trp-d-Cys]-Pro-Pro-Lys-Asp-NH2 -
Similarity Score 0.66
HY-19870CSetmelanotide monoacetate -
Explore the MedChemAI to find more analogs
![Ac-c[Cys-Glu-His-d-Phe-Arg-Trp-d-Cys]-Pro-Pro-Lys-Asp-NH2 Chemical Structure](http://file.medchemexpress.com/product_pic/hy-p4665.gif)
References
- [1]. S. Kaushal, et al. Complement C3 inhibitor POT-4: Clinical Safety of Intravitreal Administration. ARVO Annual Meeting Abstract, 2009 Apr.
- [2]. Robyn Troutbeck, et al. Therapeutic targeting of the complement system in age-related macular degeneration: a review. Clin Exp Ophthalmol. Jan-Feb 2012;40(1):18-26. [Content Brief]
